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Th17 cellsAbstract Aim of the work: To investigate the role of T-helper 17 (Th17) cells in peripheral blood
and serum interleukin-17 (IL-17) in rheumatoid arthritis (RA) patients, and their correlation with
disease activity and joint destruction.
Patients and methods: This study included forty RA patients and twenty matched healthy
controls. Disease activity score in 28 joints (DAS-28), erythrocyte sedimentation rate (ESR),
C-reactive protein (CRP), rheumatoid factor (RF), anti-CCP, tumor necrosis factor alpha (TNF-a),
serum IL-17 and Th17 cells in peripheral blood were measured. Radiological assessment using mod-
iﬁed Sharp/van der Heijde (mSvH) score for hand and feet in addition to MRI score for the wrist
and metacarpophalangeal (MCP) joints were performed for detection of synovitis and bone erosion.
Results: The patients were 38 females and 2 males with a mean of 41.15 ± 5.85 years and disease
duration of 15.6 ± 4.62 years. Serum IL-17 and Th17 cells in peripheral blood were found to be
signiﬁcantly increased in RA patients (204.1 ± 33.8 pg/ml and 4.62 ± 1.13%) than in controls
(25.36 ± 5.39 pg/ml and 0.7 ± 0.021%) (p< 0.001). Th17 cells signiﬁcantly correlated with serum
IL-17 (r 0.88, p< 0.001). Both Th17 cells and serum IL-17 signiﬁcantly correlated with DAS-28,
ESR, CRP, TNF-a, Van der Heijde modiﬁcation score and MRI scores for wrist and MCP joints
for synovitis and bone erosion (all with a p< 0.001).
Conclusion: This study demonstrates an important role for Th-17 cells and serum IL-17 in the
pathogenesis of the inﬂammatory and destructive pattern characteristic of RA.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Rheumatic
Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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Rheumatoid arthritis (RA) is a systemic autoimmune disease
characterized by chronic inﬂammatory response and tissue
damage in peripheral synovial joints [1]. The etiology and
pathogenesis of RA remain unknown, it is generally
considered an autoimmune pathology in which autoreactive
T cells of pathogenic potential, such as Th1 and Th17 cells,
are thought to play an important role [2,3].
Th17 cells selectively produce the signature cytokines such
as interleukin 17 (IL-17), IL-21 and IL-22, and have been
demonstrated to play a critical role for the chronic inﬂamma-
tory response and subsequent tissue damage in RA affected
joints [4]. Moreover, IL-23 is a pro-inﬂammatory cytokine
involved in differentiation and activation of Th17 cells to pro-
duce IL-17 which was found to play a critical role in other
rheumatic diseases as inﬂammatory bowel disease (IBD) [5]
and Behc¸ets disease [6].
Interleukin 17 is highly expressed in the synovium and syn-
ovial ﬂuid of RA patients. T cells and the cytokines, IL-17 and
tumor necrosis factor alpha (TNF-a) have been shown to
activate RA synovial ﬂuid resulting in the expression of
pro-inﬂammatory cytokines such as IL-6 and IL-8, which are
mediators of joint inﬂammation [7]. Th17 cells produce
IL-17 in response to several cytokines. IL-17 affects osteoclast
differentiation indirectly by inducing the expression of Recep-
tor activator of nuclear factor kappa-B ligand (RANKL) on
the surface of osteoblasts and synoviocytes [8,9]. In a study
on Egyptian patients it has also been suggested that the T
helper 17 (Th17)/Regulatory T-cell (Treg) imbalance and the
increased level of IL-17 may be responsible for the develop-
ment and progression of RA [10].
The aim of this work was to investigate the role of Th17
cells in peripheral blood and serum IL-17 in RA patients
and to study their correlation with disease activity and joint
severity.2. Patients and methods
Forty rheumatoid arthritis patients were selected from the out-
patient clinic of the Rheumatology and Rehabilitation depart-
ment, Tanta University Hospitals, Egypt, and fulﬁlled the 2010
American College of Rheumatology (ACR)/European League
against Rheumatism (EULAR) classiﬁcation criteria for
rheumatoid arthritis [11]. All patients were under disease
modifying anti-rheumatic drugs (DMARDs), low dose corti-
costeroids and/or NSAIDs. In addition, 20 healthy volunteers
matched in age and genders were included in this study.
Informed consent was obtained from all subjects and the study
was approved by the local ethics committee.
Full history taking and clinical examination were per-
formed to the RA patients. Disease activity was assessed by
measuring the disease activity score for 28 joints (DAS-28)
[12]. Patients and control groups were subjected to the following
laboratory Investigations: Complete blood count (Advia60 cell
counter; Bayer), erythrocyte sedimentation rate (ESR) mm/1st
hour (Westergren method), serum C-reactive protein (CRP)
(CRP–latex slide agglutination test; SPINREAT, S.A.U,
Spain), rheumatoid factor (RF) (nephelometry method,
Behring, Marburg, Germany), serum anti-cyclic citrullinatedpeptide (anti-CCP3) (ELISA, Quanta Lite CCP version 3.1
for IgG/IgA from Inova Diagnostics, San Diego, CA) [13]
and serum TNF-a level (Quantikine Human TNF-a ELISA
kits, Roche Diagnostics GmbH, Mannheim, Germany) [14].
Measurement of interleukin-17 was done by ELISA [15].
The Th-17 cells were assessed by ﬂow cytometric analysis:
Mononuclear cells were incubated with PMA (50 ng/ml) and
ionomycin (1 lg/ml) plus brefeldin A (10 lg/ml) for four
hours. Cells were blocked with 50% human serum and 0.5%
bovine serum albumin in phosphate buffered saline and
incubated with allophycocyanin conjugated monoclonal
anti-CD3 (labeled by FITC) for 30 min, ﬁxed with 2%
formaldehyde for 10 min, and then permeabilized with 0.1%
NP40 for 10 min. Cells were then stained for ﬂuorescein isoth-
iocyanate labeled anti-CD4 and phycoerythrin-conjugated
anti-IL-17 (eBioscience, San Diego, CA) or isotype control
antibodies (eBioscience, San Diego, CA). Th-17 cells were
identiﬁed as those that were CD3 + CD4 + IL-17+. The
percentage of Th-17 cells in each sample was normalized for
staining with its control IgG value by subtracting the percent-
age of cells that were positive when stained with the control
IgG alone from the original percentage of Th-17 cells [16].
Radiographs in a standard posteroanterior (PA) view of the
hands/wrists and anteroposterior (AP) view of the feet were
taken with ﬁlms and scored by two independent and experi-
enced readers according to the modiﬁed Sharp/van der Heijde
(mSvH) score. The mSvH erosion score includes 16 areas from
each hand and wrist, each side of the 10 metatarsophalangeal
(MTP) and the 2 intraphalangeal joints of the big toes. The
erosions are deﬁned as: 0 = Normal, 1 = Discrete erosions,
2–3 = Larger erosions according to surface area involved,
4 = Erosions extending over middle of the bone, and
5 = Complete collapse. The mSvH joint space narrowing score
includes 15 areas from the hands and wrists and six areas from
the feet and was scored from 0 to 4, as follows: 0 = Normal,
1 = Focal narrowing, 2 = Reduction of less than 50% of joint
space, 3 = Reduction of greater than 50% of joint space and
4 = Ankylosis. The maximum erosion score is 160 for hands
and wrists and 120 for feet. The maximum joint space
narrowing score is 120 for hands and wrists and 48 for feet.
Therefore, the total mSvH radiographic score ranges from 0
to 448 [17,18].
Magnetic resonance imaging (MRI) protocol: MRI
examinations were performed using 3 T units (Optima 450w,
GE, Healthcare, Milwaukee, Wis) equipped with a linear circu-
lar 11-cm surface coil. In each patient, the most affected hand
was studied positioned in the magnet in neutral rotation. Cor-
onal and axial images of the wrist and the 2nd–5th ﬁngers were
obtained. All patients had T1-weighted image spin-echo coro-
nal pulse sequences, coronal short tau inversion recovery
(STIR) pulse sequences, and axial T2-weighted image turbo
spin-echo fat-suppressed pulse sequences. After intravenous
application of gadolinium diethylene-triamine-penta-acetic
acid (Gd-DTPA; 0.1 mmol/kg of body weight), coronal and
axial spin-echo T1-weighted fat-suppressed pulse sequences
were performed. The imaging parameters for the T1-weighted
images were as follows: repetition time (TR), 380–500 ms; echo
time (TE), 16 ms; matrix, 256 · 512; ﬁeld of view (FOV),
140–170 mm; slice thickness, 3 mm; slice gap, 0.3 mm; number
of signals averaged (NSA), 2. The STIR acquisition parameters
were as follows: TR, 2230 to 2330 ms, TE, 17 ms; inversion time
Table 2 Radiological parameters in rheumatoid arthritis
patients (n= 40).
Modiﬁed Sharp/van der Heijde (mSvH) score
Number of erosion in hands 6.10 (0–15)
Number of JSN in hands 43.86 (14–79)
Number of erosion in feet 1.43 (0–6)
Number of JSN in feet 9.10 (0–20)
Total score 60.50 (20–102)
MRI wrist joints scores
Synovitis 5.3 (2–8)
Bone erosions 3.2 (1–12)
Bone defects 2.2 (0–7)
Bone edema 1.5 (0–12)
MRI MCP joints scores
Synovitis 7.7 (3–11)
Bone erosions 2.4 (0–11)
Bone defects 1.2 (0–6)
Bone edema 0.5 (0–10)
Values are mean (interquartile ranges) JSN, joint space narrowing;
MCP, metacarpophalangeal.
Table 3 Correlation between Th-17(%) cells and serum levels
of IL-17 with clinical, laboratory and radiological data in
rheumatoid arthritis patients (n= 40).
Parameter Rheumatoid arthritis patients (n= 40)
Th-17 cells Serum IL-17
r p r p
Age (years) 0.071 NS 0.045 NS
Role of Th-17 cells and IL-17 in rheumatoid arthritis patients 3(TI), 160 ms; matrix, 256 · 512; FOV, 140–170 mm; slice
thickness, 3 mm; slice gap, 0.3 mm; NSA, 2. The fat-suppressed
T2-weighted image parameters were as follows: TR, 2600 ms;
TE, 90 ms; matrix, 256 · 512; FOV, 100–140 mm; slice
thickness, 3 mm; slice gap, 0.3 mm; NSA, 4.The fat-suppressed
T1-weighted post-Gd-DTPA image parameters were as
follows: TR, 450 ms; TE, 15 ms; matrix, 256 · 256; FOV,
100–170 mm; slice thickness 3 mm; slice gap, 0.3 mm; NSA, 2.
2.1. Image evaluation
All the MRIs were scored for synovitis, bone edema and bone
erosions, as deﬁned in the Outcome Measures in Rheuma-
tology (OMERACT) MRI rheumatoid arthritis recommenda-
tions [19] by two radiologists who were blinded to the clinical
ﬁndings.
2.1.1. Scoring of synovitis
Synovitis was demonstrated by gadolinium enhancement of
the synovial compartment. A global score scale of 0–3 was
used. A score of 0 indicated a normal synovial compartment
with no synovial enhancement or an area of enhancement that
was no thicker than the joint capsule. Scores of 1, 2, and 3,
respectively, indicated areas of mild, moderate, and severe
enhancement that were thicker than the joint capsule. These
global scores were assigned to each of four MCP joint sites,
yielding an aggregated score of 0–12. In the wrist, the global
score was assigned at three sites: the radioulnar, radiocarpal,
and intercarpal- carpometacarpal joints, yielding an
aggregated score of 0–9.
2.1.2. Scoring of bone lesions
Bone lesions were scored from 0 to 10 in 10% increments
according to the volume of the erosion as a proportion of
the assessed bone volume and judged on all available images.
For the carpal bones, the assessed bone volume was that of
the whole bone. For the MCP joints (2nd–5th), the assessed
bone volume included a bone portion 1 cm deep from theTable 1 Demographics features, disease activity and labora-
tory parameters in rheumatoid arthritis patients and controls.
RA patients (n= 40) Controls (n= 20)
Age (years) 41.15 ± 5.85 42.7 ± 6.79
Sex (male/female) 2/38 1/19
Disease duration (years) 15.60 ± 4.6 –
DAS-28 4.43 ± 0.7 –
ESR (mm/1st h) 40.75 ± 15.5* 12.63 ± 1.36
CRP (mg/dl) 22.32 ± 4.7* 1.79 ± 0.87
RF (IU/ml) 70.57 ± 20.4* 8.50 ± 2.56
Anti-CCP3 (U/ml) 240.6 ± 88.6* 11.60 ± 2.75
TNF-a (pg/ml) 11.13 ± 2.9* 3.71 ± 0.97
IL-17 (pg/ml) 204.1 ± 33.8* 25.36 ± 5.39
Th-17 cells (%) 4.62 ± 1.13* 0.70 ± 0.21
The values represent the mean ± SD. DAS-28, disease activity for
28 joint indices score; ESR, erythrocyte sedimentation rate; CRP, C
reactive protein; RF, rheumatoid factor; anti-CCP, anti-cyclic
citrullinated peptide; TNF-a, tumor necrosis factor-a; IL-17,
interleukin-17; Th-17, T helper 17.
* Signiﬁcantly different compared to controls.cortex of the articular surface or the best estimated position
of the cortex of the arterial surface if this cortex was absent
(because of an erosion). Erosions were deﬁned as sharply
marginated areas of trabecular bone loss with a cortical break.
Bone defects were deﬁned as sharply marginated areas of tra-Disease duration (years) 0.173 NS 0.213 NS
DAS-28 0.939 <0.001* 0.892 <0.001*
ESR (mm/1st hr) 0.882 <0.001* 0.684 <0.001*
CRP (mg/dl) 0.765 <0.001* 0.696 <0.001*
RF (IU/ml) 0.032 NS 0.257 NS
Anti-CCP (U/ml) 0.231 NS 0.210 NS
TNF-a (pg/ml) 0.634 <0.001* 0.537 <0.001*
IL-17 (pg/ml) 0.884 <0.001* – –
mSvH score 0.643 <0.001* 0.663 <0.001*
MRI score for synovitis
Wrist joints 0.432 <0.001* 0.467 <0.001*
MCP joints 0.653 <0.001* 0.631 <0.001*
MRI score for erosion
Wrist joints 0.671 <0.001* 0.761 <0.001*
MCP joints 0.712 <0.001* 0.451 <0.001*
*Pearson’s correlation coefﬁcient. NS: non-signiﬁcant, * = signiﬁ-
cantly different compared to controls. DAS-28, disease activity for
28 joint indices score; ESR, erythrocyte sedimentation rate; CRP, C
reactive protein; RF, Rheumatoid factor; anti-CCP, anti-cyclic
citrullinated peptide; TNF-a, tumor necrosis factor-a; IL-17,
interleukin-17; Th-17, T helper 17; mSvH, modiﬁed Sharp/van der
Heijde; MRI, magnetic resonance imaging; MCP,
metacarpophalangeal.
4 H.M. Al-Saadany et al.becular bone loss without a visible cortical break. Bone edema
could occur alone or surround a defect or erosion and was
deﬁned as a lesion with ill-deﬁned margins that was neither
erosion nor a defect and had high signal intensity on T2-
weighted STIR MR images. For the MCP joints, the locations
of bone abnormalities (ie, involvement of radial, ulnar, pal-
mar, and dorsal quadrants) were also speciﬁed. One abnor-
mality (erosions, defects and edema) was assigned to 14 sites
(distal portion of radius; distal portion of ulna; scaphoid,
lunate, triquetrum, pisiform, trapezium, trapezoid, capitate,
and hamate bones; and the bases of the 2nd–5th metacarpal
bones) on the wrist joint images and to eight sites (metacarpal
head and phalangeal base of each 2nd–5th MCP joint) on the
MCP joint images. Therefore, the aggregated scores for wrist
and MCP joints ranged from 0 to 140 and from 0 to 80,
respectively, with respect to bone erosions, bone defects and
bone edema.
Statistical analysis: All data were analyzed using the soft-
ware SPSS (version 11, SPSS Inc., Chicago, Illinois). Baseline
characteristics are presented as mean ± standard deviation for
the continuous variables, and as frequency and percentage for
the discrete ones. Comparisons between groups were conduct-
ed using the Student t-test. Correlation between variables was
examined using the Pearson’s correlation coefﬁcient. Multiple
linear regression analysis was used to determine the indepen-
dent predictors of serum IL-17 and Th-17 cells. p value
<0.05 was considered statistically signiﬁcant.Figure 1 MRI of the hand and wrist revealed bone marro3. Results
The demographics, clinical and laboratory data for patients
with RA and controls are summarized in Table 1. Thirty-eight
patients were females, while 2 were males, their ages ranged
from 36 to 50 years with a mean of 41.15 ± 5.85 years. Mean-
while, 19 of controls were females and 1 was male, their ages
ranged from 34 to 51 years with a mean of 42.7 ± 6.79 years.
There was no signiﬁcant difference in age and sex between RA
patients and controls.
In RA patients, laboratory parameters including ESR,
CRP, TNF-a, RF and anti-CCP3 levels were signiﬁcantly
higher in RA patients compared to controls. Serum IL-17
and Th-17 cell percentages were signiﬁcantly higher in RA
patients compared to controls (p< 0.001). Table 2 demon-
strates radiographic data in the current RA patients assessed
by the mSvH score for standard PA view of the hands/wrists
and AP view of the feet; in addition to the MRI scoring system
for detection of synovitis, bone edema and erosions. Active
synovitis was found in the wrist and MCP joints in all patients.
In the wrist joints, bone erosions were seen in all patients
(100%) and bone edema in 15 (37.5%). In the MCP joints,
bone erosions were seen in 22 (55%) and bone edema in 26
(65%).
There were signiﬁcant correlations between Th-17 cell
percentages with serum levels of IL-17 and both signiﬁcantly
correlated with disease activity (DAS-28), ESR, CRP andw edema and erosion of the wrist and all carpal bone.
Role of Th-17 cells and IL-17 in rheumatoid arthritis patients 5TNF-a. Both Th-17 cell percentages and serum levels of
IL-17 signiﬁcantly correlated with the total mSvH score and
MRI scores for synovitis and erosions (Table 3). As regard
multiple linear regression analysis, Th-17 cells were signiﬁcant-
ly associated with serum IL-17 levels (b= 0.56; p< 0.001),
DAS-28(b= 0.3; p< 0.001), TNF-a (b= 0.39; p< 0.001),
total mSvH score (b= 0.45; p< 0.001) and MRI score for
erosions (b= 0.49; p< 0.001). Figure 1 shows an MRI of
the hand and wrist with bone marrow edema and erosion of
the wrist and all carpal bone.4. Discussion
Dysregulation of cytokine production or action is thought to
have a central role in the development of RA. Previously,
RA had been considered a Th1-cell-mediated disorder, and
therefore was thought to be driven by a population of T cells
producing inﬂammatory cytokines such as IL-2, TNF and
interferons [20]. It has been suggested that overproduction of
IL-17 and up-regulation of Th17 cells are common features
of RA [21].
Our study showed that the percentage of Th17 cells and serum
levels of IL-17was signiﬁcantly increased inRApatients compar-
ing to controls. (p< 0.001). Hemdan et al. [4] and Dong et al.
[22], concluded that among CD4+, T-helper cell subsets are the
most prominent ‘‘Th17’’cells, constituting a distinct lineage of T
cells bridging the innate and adaptive immunity. These Th17 cells
are characterized by expression of the transcription factors reti-
noic acid-related orphan nuclear receptor (RORct & RORa),
the surface markers CCR4, CCR6 & IL-23R, the production of
the potent proinﬂammatory molecules IL-17, IL-17F, IL-21,
IL-22, IL-26 and G-CSF as well as the chemokine CCL20.
Therefore, Th17 cells are potent inﬂammatory mediators that
are due to the ubiquitous expression of their effecter cytokine
receptors, with manifold contributions to a growing list of disor-
ders including asthma, allergy, psoriasis, RA, lupus and IBD.
In the present study the IL-17 level increased 8 folds the
level in the control. In another study on Egyptian RA patients,
the level of IL-17 increased 5 folds compared to the control
[10]. Turner et al. [23] reported that the discovery of IL-17 pro-
ducing CD4+ T (Th17) cells as a unique T-helper cell lineage
has revised our understanding of T-cell-mediated tissue injury.
Autoimmune diseases such as multiple sclerosis and RA, clas-
sically believed to be Th1-mediated, are predominantly driven
by a Th17 immune response. IL-17 (IL-17A, IL-17F, IL-21,
IL-22) and possibly also IL-9 produced by Th17 cells promote
inﬂammation by directly causing tissue injury and enhancing
secretion of pro-inﬂammatory cytokines and chemokines by
resident cells. This results in augmented inﬁltration of
leukocytes, in particular neutrophils to the affected tissue where
they induce organ inﬂammation and injury. On synoviocytes,
IL-1b, TNFa, and IL-17 were shown to induce production
of IL-6 and leukemia inhibitory factor (LIF) [24]. Using low
concentrations of IL-17 and IL-1b in combination, a synergistic
effect on the production of IL-6 was observed, whereas an
additive effect was observed on the production of LIF. Both
IL-4 and IL-13 had a modest stimulatory effect on the IL-1
and IL-17 induced production of IL-6, but both inhibited
production of LIF. These ﬁndings indicate that low levels of
cytokines produced by monocytes (IL-1) and T cells (IL-17)
can act together on synoviocytes and contribute to the recruit-ment of T cells and dendritic cells by enhancing the production
of CCL20. Thus, some RA synovium T cells producing IL-17
can activate mesenchymal cells, leading to an increased
proinﬂammatory pattern that is sensitive, in part, to
Th2-cytokine regulation [25].
In this study, there were signiﬁcant correlations between
Th-17 cell percentages and serum levels of IL-17 with disease
activity (DAS-28), ESR, CRP, TNF-a and MRI score of syn-
ovitis, and scores for disease severity and joint destruction
(mSvH and MRI erosions). Many studies demonstrate that
IL-17 is produced in the RA synovium. More interestingly,
IL-17 triggers human synoviocytes to produce IL-6, IL-8,
GM-CSF and one of the major mediators of inﬂammation,
PGE2 [26–28]. The list of biological effects of IL-17 includes
triggering of the production of TNF-a, IL-1b, IL-12, stromely-
sin, IL-10, and IL-1R antagonist in human peripheral blood
macrophages [29]. In the study on Egyptian RA patients, even
though IL-17 serum level did not correlate with the DAS28
score yet it was signiﬁcantly higher among severely active
patients as compared to patients with moderate activity [8].
Cartilage degradation can also be induced by IL-17 inhibit-
ing PG synthesis and increasing its destruction. IL-17 has also
already been shown to induce nitric oxide and stromelysin
expression by isolated chondrocytes [30,31] and administration
of IL-17 into normal knee was, more importantly, able to
induce such degradation [32]. It is important to notice that
such effect was observed using IL-17 alone and not in an
inﬂamed joint where IL-1, TNF-a and IL-17 would have been
already present. The endogenous secretion of IL-17 from the
cartilage appears unlikely and was not evaluated as IL-17 is
still considered a T-cell speciﬁc cytokine. Chabaud et al. [33]
demonstrated the role of IL-17 and thus of T cells from bone
in destruction and defective formation using speciﬁc IL-17
inhibitors. The important inhibition observed when blocking
IL-17 alone can be explained by the synergistic interaction
between IL-17 and other cytokines, as ﬁrst shown with ﬁbrob-
lasts and synoviocytes. T cells were shown to express RANKL
that is an activator of osteoclast formation also present in RA
synovium [34,35]. Administration of IL-4 in the mouse model
of collagen arthritis was able to control cartilage and bone
destruction through an inhibition of the expression of IL-1,
TNF-a, IL-17 and RANKL [36]. Cai et al. [37] have also
shown that IL-17 is a direct and potent inducer of matrix
destruction in articular cartilage explants.
A prospective study investigated the importance of cyto-
kine mRNA expression in biopsy-obtained knee synovial tis-
sue at baseline of 60 RA patients, in respect to joint damage,
as evaluated by MRI and radiography during a 2-year period
[38]. The synovial membrane mRNA levels of IL-1b, TNFa,
IL-10, and IL-17 were predictors of future joint damage. The
‘‘statistical’’ effect of IL-17 was synergistic with that of TNFa
and was more pronounced with shorter disease duration, indi-
cating a key role of IL-17 in joint destruction in RA. The
above lines of evidence suggest that IL-17 is a member of a
complex network of cytokines that mediates joint pathology
in humans. The fact that IL-17 blockade has beneﬁcial effects
on murine arthritis suggests that this form of treatment might
be effective in inﬂammatory arthritides in humans but this
remains to be proven in clinical trials.
Several investigators have focused on the potential role of
IL-17 in mediating joint damage. Koshy and coworkers [39]
studied the ability of IL-17 to induce collagen release from car-
6 H.M. Al-Saadany et al.tilage. The authors used bovine nasal cartilage explant cultures
and studied the effect of exogenously added IL-17, either alone
or in combination with other proinﬂammatory cytokines
(IL-1, IL-6, TNFa), on matrix breakdown. IL-17 stimulated
proteoglycan and collagen type II release from bovine nasal
cartilage in a dose dependent manner. Moreover, Lubberts
et al. [40] reported that the identiﬁcation of six IL-17 family
members (IL-17A–F) may extend the role of this novel
cytokine family in the pathogenesis of chronic destructive joint
inﬂammation. IL-17A is a potent inducer of RANKL and
demonstrates additive or even synergistic effects with IL-1
and TNF on inducing joint pathology. However, IL-17A has
the capacity to induce chronic destructive arthritis in an IL-1
and TNF independent way [41].
In conclusion, this study demonstrates an important role
for Th-17 cells and IL-17 in the pathogenesis of inﬂammatory
and destructive pattern characteristic of RA.
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